Baker BROS. Advisors LP raised its stake in Generation Bio Co. (NASDAQ:GBIO - Free Report) by 61.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,944,945 shares of the company's stock after purchasing an additional 737,988 shares during the period. Baker BROS. Advisors LP owned 2.91% of Generation Bio worth $4,804,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of GBIO. Vanguard Group Inc. increased its stake in Generation Bio by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,570,456 shares of the company's stock valued at $10,462,000 after purchasing an additional 18,205 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Generation Bio by 31.2% during the second quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company's stock valued at $527,000 after buying an additional 44,378 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Generation Bio by 7.4% during the second quarter. Rhumbline Advisers now owns 78,903 shares of the company's stock valued at $222,000 after buying an additional 5,430 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Generation Bio by 23.9% during the second quarter. Acadian Asset Management LLC now owns 594,569 shares of the company's stock valued at $1,675,000 after buying an additional 114,734 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Generation Bio by 199.3% during the second quarter. American Century Companies Inc. now owns 31,786 shares of the company's stock valued at $90,000 after buying an additional 21,167 shares during the last quarter. 95.22% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on the stock. Wedbush reiterated an "outperform" rating and set a $5.00 price objective on shares of Generation Bio in a report on Thursday, November 7th. Needham & Company LLC restated a "buy" rating and set a $10.00 price target on shares of Generation Bio in a report on Wednesday, October 23rd.
Read Our Latest Stock Analysis on Generation Bio
Generation Bio Stock Performance
GBIO stock traded down $0.10 during mid-day trading on Monday, hitting $1.42. The company had a trading volume of 187,503 shares, compared to its average volume of 180,768. The firm has a market cap of $94.85 million, a PE ratio of -0.66 and a beta of 2.82. Generation Bio Co. has a 12 month low of $1.24 and a 12 month high of $4.65. The stock's fifty day moving average price is $2.12 and its two-hundred day moving average price is $2.56.
Generation Bio Profile
(
Free Report)
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
Read More
Before you consider Generation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Generation Bio wasn't on the list.
While Generation Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.